24 completed, 20 recruiting, 18 unknown, 7 not yet recruiting. 79 Phase 3, 15 Phase 2.
Follow Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Esophageal Squamous Cell Carcinoma trials Research Report on Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Henan Cancer Hospital | 1044 | 2026-06-16 | 2026-07-31 |
| A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 90 | 2026-06-09 | 2026-07-16 |
| QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 466 | 2026-04-20 | 2026-04-24 |
| Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study Toripalimab - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 340 | 2026-03-23 | 2026-10-23 |
| Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF） - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Tang-Du Hospital | 390 | 2026-02-01 | 2026-01-30 |
| A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. SYS6010+SG001+ physician's choice (Capecitabine or 5-FU), Investigator's choice of SOC, SYS6010+SG001 - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 737 | 2025-12-30 | 2025-11-26 |
| Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC toripalimab, capecitabine - Esophageal Cancer, Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 242 | 2025-09-10 | 2026-04-21 |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Ifinatamab deruxtecan, Docetaxel, Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Daiichi Sankyo | 510 | 2025-03-27 | 2026-10-26 |
| Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)] - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 / Phase 3 | Not yet recruiting | YIN LI | 474 | 2025-03-01 | 2025-03-11 |
| Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC liposomal irinotecan, 5-FU, LV - Esophageal Cancer | Phase 3 | Not yet recruiting | Rui-hua Xu, MD, PhD | 360 | 2024-08-01 | 2024-07-15 |
| Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy Sintilimab Combined With Docetaxel Monotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Enrolling by invitation | Ye jinjun | 79 | 2024-08-01 | 2025-06-12 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) BL-B01D1, Irinotecan, paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 497 | 2024-03-19 | 2026-07-23 |
| A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma anlotinib, Thoracic radiotherapy - Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Army Medical Center of PLA | 266 | 2024-03-08 | 2024-04-09 |
| A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer KC1036, Irinotecan, Docetaxel - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Beijing Konruns Pharmaceutical Co., Ltd. | 490 | 2024-02-05 | 2024-03-07 |
| Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma PEG-rhG-GSF - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 40 | 2024-02-02 | 2024-08-21 |
| Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma Chemotherapy, Immunotherapy (Pembrolizumab), radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Peking Union Medical College Hospital | 120 | 2024-01-12 | 2025-04-02 |
| A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma LY01015, Fluorouracil, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | Shandong Boan Biotechnology Co., Ltd | 510 | 2023-10-12 | 2026-10-13 |
| Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab） - Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Qingdao Central Hospital | 90 | 2023-09-20 | 2024-07-24 |
Showing 20 of 79. Sign in to see all of them.
Esophageal Neoplasms (18) · Adenocarcinoma Of Esophagus (10) · Carcinoma, Squamous Cell (2) · Neoplasm Metastasis (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Head and Neck Neoplasms (1)
Carcinoma (79) · Digestive System Diseases (79) · Digestive System Neoplasms (79) · Gastrointestinal Neoplasms (79) · Neoplasms (79) · Neoplasms by Histologic Type (79) · Neoplasms by Site (79) · Neoplasms, Glandular and Epithelial (79) · Esophageal Diseases (78) · Gastrointestinal Diseases (78) · Head and Neck Neoplasms (78) · Neoplasms, Squamous Cell (78) · Carcinoma, Squamous Cell (77) · Esophageal Neoplasms (61) · Pathologic Processes (3)
Cisplatin (29) · Radiotherapy (22) · Fluorouracil (20) · Paclitaxel (18) · Docetaxel (9) · Irinotecan (8) · Neoadjuvant Therapy (8) · Drug Therapy (7) · Capecitabine (6) · Esophagectomy (6) · Radiation (6) · tislelizumab (6) · Leucovorin (5) · Oxaliplatin (5) · Surgical Procedures, Operative (5)
Fudan University (8) · Sun Yat-sen University (6) · The First Affiliated Hospital of Henan University of Science and Technology (6) · BeiGene (3) · Henan Cancer Hospital (3) · Merck Sharp & Dohme LLC (2) · Radiation Therapy Oncology Group (2) · Shanghai Zhongshan Hospital (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Sichuan Cancer Hospital and Research Institute (2) · Tianjin Medical University Cancer Institute and Hospital (2) · UNICANCER (2) · AIO-Studien-gGmbH (1) · Alliance for Clinical Trials in Oncology (1) · Army Medical Center of PLA (1)
China (57) · France (13) · United States (11) · Japan (9) · Taiwan (9) · Belgium (8) · Germany (8) · South Korea (8) · United Kingdom (8) · Italy (7) · Spain (7) · Canada (6) · Hungary (5) · Russia (5) · Poland (4)
Shegan Gao, Doctor (4) · Tanyou Shan, Master (4) · Xiaozhi Yuan, Master (4) · Dan Wang, Master (3) · Guoqiang Kong, Master (3) · Jiachun Sun, Doctor (3) · Jing Ren, Master (3) · Ruina Yang, Master (3) · Ruinuo Jia, Master (3) · Shiyuan Song, Master (3) · Wei Wang, Master (3) · Weijiao Yin, Master (3) · Xiaoshan Feng, Doctor (3) · Xinshuai Wang, Doctor (3) · Yali Zhang, Master (3)
PMID 24982463, PMID 38710003, PMID 40373876, PMID 11391598, PMID 11870157, PMID 16235286, PMID 18309943, PMID 19465425, PMID 21673875, PMID 21684205, PMID 21918956, PMID 22867894, PMID 23165781, PMID 23274533, PMID 23865505, PMID 24556041, PMID 24907633, PMID 25361220, PMID 26511668, PMID 28687830, PMID 29482649, PMID 29635438, PMID 30089078, PMID 30344165, PMID 30920880, PMID 31959339, PMID 32111181, PMID 32293362, PMID 32877795, PMID 32883216, PMID 33055589, PMID 33533655, PMID 34160577, PMID 34269067, PMID 34817733, PMID 35188552, PMID 35280748, PMID 35433421, PMID 35440464, PMID 35442766, PMID 35785595, PMID 35906623, PMID 35912196, PMID 36115002, PMID 36732627, PMID 36910109, PMID 36990609, PMID 37080222, PMID 37131154, PMID 37139963
2009 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), U10CA031946 (1)